A new drug, according to the first tests, shows that it can stop some tumors of breast cancer from using hormones to grow.

The clinical trial Serena-6conducted in collaboration with the London Cancer Research Institute, shows that the use of camizstrant can slows down her progression of the disease and delay chemotherapy.

According to the Cancer Research UK and as Sky News reports, the drug prevents estrogen from entering the breast cancer cell, which researchers hope that it can then stop or slow down cancer.

Patients with breast cancer who received the drug in the test reduced the chances of developing the disease by 52% compared to well -known treatments.

The teacher Christian HellenManaging Director of the Cancer Research Institute said the results “They represent more than a clinical milestone. They represent a transformative change in the way we approach precision medicine. “

Researcher Professor Nick Turner also described the development of the drug as “A key moment in the care of breast cancer”.

The study, funded by the Astrazenecaexamined patients with breast cancer who is positive in hormonal receptors and negative in HER2. These are a type of cancer that develops about 70% of patients.

More than 3,000 patients from 23 countries took part in the third phase of the testin which doctors through blood test They detected changes in cancer DNA to see what treatments were ineffective.

For those who received Camizestrant, their cancer stabilized for about 16 months on average, compared to about 9 months given other treatments.

However, the 1% of patients who received the new drug stopped to take it due to side effects.

Further results from the Serena-6 test will be presented at the annual meeting of the American Society of Clinical Oncology in Chicago on Sunday.

It is also about first world study that has shown that the use blood test To find early indications of cancer in treatment it helps patients.

OR Dr. Kathryn EliotResearch Director at Cancer Research UK, praised the discovery as one “A clear example of how blood tests begin to transform cancer treatment.”

‘By monitoring tiny blood DNA tumor traces, the researchers were able to identify Early signs of treatment resistance and change treatment before cancer prevents developing‘he added.

“It shows how it circulates DNA (CTDNA) could help doctors make smarter and timely treatment decisions. This approach could become a significant part of personalized care for people with advanced breast cancer, “he said.